Skip to main content
Research at Children's Research Institute involving the use of biohazardous materials, including recombinant deoxyribonucleic acid (DNA), agents infectious to humans or animals and genetically altered organisms and agents require IBC approval.
back to top
A principal investigator is a member of the faculty or staff who bears responsibility for the intellectual leadership of a project. The principal investigator accepts overall responsibility for directing the research and for the financial oversight of the award's funding, as well as compliance with relevant policies and sponsor terms and conditions of award.
Please email the IBC.
Biohazards are infectious agents or hazardous biological materials that present a risk or potential risk to the health of humans, animals or the environment. The risk can be direct through infection or indirect through damage to the environment.
Biohazardous materials include certain types of recombinant DNA; organisms and viruses infectious to humans, animals or plants (e.g., parasites, viruses, bacteria, fungi, prions, rickettsia); and biologically active agents (i.e. toxins, allergens, venoms) that may cause disease in other living organisms or cause significant impact to the environment or community.
The Centers for Disease Control (CDC) provides documentation on their website.
You must obtain approval from the IBC on any changes prior to their implementation.
Gene Regulation: Development, Differentiation and Disease
Ethical Implications of Transplantation in Children with Profound Disabilities
Parental Decision-Making in the ICU: Neurology, Genetics and Uncertainty
Hematopoietic Cell Transplantation as an Immune-Tolerizing Platform for Solid Organ Transplantation
Toward Novel Immune Tolerance Protocols in Hemophilia
Seattle Children’s provides healthcare for the special needs of children regardless
of race, sex, creed, ethnicity or disability. Financial assistance for medically
necessary services is based on family income and hospital resources and is provided
to children under age 21 whose primary residence is in Washington, Alaska, Montana
Seattle Children’s Hospital, Research